Interleukin 3 (IL-3)-dependent PB-3c mouse mastocytes can be transformed by the v-Ha-ras oncogene to generate autocrine IL-3-producing mastocytomas. Hybrid cell lines were constructed by fusing an IL-3-producing mastocytoma cell line with its IL-3-dependent normal parental cell. Unlike the mastocytoma parent cell line, hybrid cell lines required growth factor for in vitro proliferation, indicating that the IL-3-dependent phenotype is dominant. IL-3 mRNA, expressed at high levels in the tumor cells, appeared downregulated in the cell hybrids. In contrast, p21 Ha levels were not reduced in the hybrids. The hybrid lines generated tumors in vivo with drastically prolonged latency times when compared to the tumor parent (10 versus 2 weeks). We propose that down-regulation of IL-3 mRNA production after cell fusion is responsible for the loss of growth autonomy in the hybrids and is likely to play a role in the partial suppression of tumor formation in vivo. Our data are consistent with the hypothesis that a tumor suppressor, present in PB-3c cells, acts as a negative regulator of IL-3 expression.
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Cell fusion experiments and human karyotype analysis have provided evidence for the existence of recessive tumor suppressor genes (for reviews, see refs. 1 and 2). In human retinoblastoma (3), a putative suppressor gene has been cloned (4, 5) and its product was found to interact with the viral ElA oncoprotein (6) . By using cell fusion techniques, putative suppressor genes have also been localized on specific human (7, 8) and mouse (9) chromosomes. Introduction of human chromosome 11 by way of microcell fusion into tumorigenic HeLa or Wilms tumor cells resulted in the abrogation of tumorigenicity (10, 11) . Human DNA sequences suppressing rodent ras-induced tumors have been cloned (12) . In studies with tumors induced by the ras oncogenes, suppression did not involve down-regulation of the ras p21 protein but apparently acted upon a step beyond the oncoprotein (13) (14) (15) (16) . At present, the mechanism of suppression is unknown; however, a potential target could be the autocrine loop characteristic of several oncogene-induced tumor systems (17, 18) .
We have reported (18) the generation of autocrine interleukin 3 (IL-3)-secreting mastocytomas in syngeneic mice, from the v-Ha-ras-infected IL-3-dependent murine mastocyte PB-3c line: cell lines derived from these tumors grew in vitro without exogenous IL-3. Still colony formation in semi-solid medium could be blocked by anti-IL-3 antibody. High levels of IL-3 expression and abrogation of IL-3 dependence did not occur in vitro at the time when the v-Ha-ras gene was introduced into PB-3c cells but developed in vivo, apparently associated with the terminal transforming event.
In the present studies, we used somatic cell fusion to analyze the nature of the autocrine IL-3 loop. The results indicate dominance of IL-3 dependency over growth autonomy involving a mechanism down-regulating IL-3 mRNA expression.
MATERIALS AND METHODS
Cell Lines and Tissue Culture. PB-3c is a cloned, IL-3-dependent, nontumorigenic mastocyte line, derived from mouse bone marrow (19, 20) . V2D1 is one of a series of four mastocytoma lines obtained from PB-3c cells by in vitro infection with a retroviral vector carrying the neomycinresistance gene and the v-Ha-ras genes (18) . Infected cells remained initially IL-3-dependent but, after inoculation into syngeneic mice, progressed to a malignant mastocytoma phenotype. Tumor cells grew in tissue culture without added IL-3; i.e., they had acquired growth autonomy (18) . V2D1T is a HAT (0.1 mM hypoxanthine/0.45 AuM aminopterin/20 ,M thymidine)-sensitive subline of V2D1, derived by stepwise selection for growth in 0.05 mM thioguanine. Hygromycin B-resistant PB-3c cells were developed after infection of PB-3c cells with a retroviral vector carrying the hygromycin gene (J. Muser and C.M., unpublished results). PB-3c cells, hybrids (see below), and FDCP-1 cells (21) were grown in Iscove's modified Dulbecco's medium (IMDM), supplemented with 10% (vol/vol) fetal calf serum, penicillin (100 units/ml), streptomycin (100 ,ug/ml), and 50 ,uAM 2-mercaptoethanol, and conditioned medium from WEHI-3B cells (WEHI-CM) (22) , as a source of Fusion and Selection System. Fusions were performed as described by Koehler (23) . Briefly, 108 PB-3c cells and 107 V2D1T cells were pelleted by low-speed centrifugation. The pellet was gently resuspended in 0.7 ml of 50o (wt/vol) polyethylene glycol 1500 (PEG) (Merck) in IMDM. After incubation for 90 s at 37°C, PEG was diluted with serum-free IMDM, cells were centrifuged and then suspended in IMDM containing WEHI-CM. Selection was applied after 24 hr by adding HAT and the neomycin analogue G418 (1 mg/ml) to the medium to select against V2D1T and PB-3c cells, respectively. Selection was done in parallel in suspension culture or in semi-solid medium (24) . In the latter procedure, the cloning medium contained 1.2% (wt/vol) methylcellulose, 1% bovine serum albumin, 20%o fetal calf serum, iron-saturated human transferrin (300 ,g/ml), and WEHI-CM in addition to the selection agents. Approximately 105 cells were plated 24 hr after fusion in 1 ml ofcloning medium and incubated in 35-mm diameter dishes. Microscopic colonies were picked 14 
RESULTS
To select for hybrids between an autocrine mastocytoma line and its nontumorigenic IL-3-dependent parental mastocyte line, a HAT-sensitive mastocytoma subline was first isolated. The corresponding cell line V2D1T (HAT sensitive and resistant to the neomycin analogue G418) was fused to PB-3c mastocyte line (HAT resistant and G418 sensitive). Independently selected hybrid lines contained the expected neartetraploid set of chromosomes (data not shown). When growth in the absence of IL-3 was measured, five independent hybrid lines from two fusion experiments resembled the PB-3c parent in that they did not grow in IL-3-free medium (Fig. 1) . Viability of hybrid cells and PB-3c dropped sharply after IL-3 removal to less than 1% as opposed to greater than 95% in V2D1T. Thus IL-3 dependence behaves as a dominant trait, suppressing the autocrine tumor phenotype.
After more than 6 months of continuous tissue culture of V2D1T, the IL-3-independent phenotype could rarely be suppressed upon fusion with the IL-3-dependent PB-3c cell line (data not shown). Therefore, we analyzed the original V2D1 mastocytoma line (from which V2D1T was derived) by fusing it with a hygromycin-resistant PB-3c cell line. Hygromycin/G418-resistant hybrid cell lines were isolated from the methylcellulose cloning selection medium. All 22 clones tested were IL-3-dependent (data not shown). We conclude that most clones of this mastocytoma cell line show IL-3 dependence after cell fusion, but non-suppressible cells are generated after prolonged periods in tissue culture.
Because the tumors were induced by the v-Ha-ras oncogene, we next determined whether the loss of growth autonomy in the cell hybrids might be correlated with a reduction in the expression of the v-Ha-ras p21 gene product. Both parental lines and the hybrid cells were labeled with [35S]-methionine and analyzed by immunoprecipitation with monoclonal anti-p21 antibody (25) . The results, presented in Fig. 2 , show that hybrid cells and V2D1T cells contain similar levels of p21, whereas no p21 was detectable in PB-3c cells. We conclude that the difference in phenotype between mas- tocytoma and hybrid cells is not due to an alte v-Ha-ras expression. We next examined the possil the production of IL-3 was affected and determine( mRNA levels by Northern blot analysis (Fig. 3) . IL-3-specific band of the expected 1-kilobase size (Fig. 3A) . The upper bands in Fig. A strong 3A correspond to genomic and subgenomic vector tran- (29) was scripts, respectively. When the same filter was washed and rehybridized with a v-Ha-ras probe, hybrids and tumor cells, but not PB-3c cells, displayed the expected transcripts (Fig.  3B) . Transcripts of c-Ha-ras (Fig. 3B) and actin (Fig. 3C) were also identified on the same filter and serve as internal standards.
The same lines were also tested for tumor formation in -28s syngeneic mice (Table 1) . By injecting mice with V2D1T cells, more than 50% of the mice developed tumors after 2 weeks. In contrast the tumor latency time of the hybrid lines was around 10 weeks. The fact that tumors arose from hybrid lines cloned immediately after fusion suggests that they did not arise from a subpopulation of nonsuppressed hybrid cells -18Os
but required an additional step to express the tumorigenic phenotype. When cells from three of these tumors were transferred to tissue culture, they were again able to grow in the absence of added IL-3, indicating they had reacquired an -L -3 IL-3-independent phenotype. Conditioned medium from these cultures elicited mitogenic activity in FDCP-1 cells. Anti-IL-3 antibody inhibited the mitogenic activity derived from two samples, showing that IL-3 production was reestablished in some of the tumor cells ( Specific tumor-suppressor chromosomes have been described (7) (8) (9) , and suppressor genes involved in human retinoblastoma (4, 5) and rodent tumors (16) have been cloned. Suppression of the type reported here could be the result of genes regulating the expression of IL-3. In the PB-3c cell line, IL-3 expression appears to be regulated at the level of mRNA stability (34) . This post-transcriptional regulation of IL-3 mRNA probably reflects a physiological property of normal mast cells that produce IL-3 in response to the activation of their IgE receptor (32) . Thus the putative suppressor gene could be a negative regulator of IL-3 mRNA.
Another possibility to explain our results could be a gene-dosage effect involving p21-Haras. However, dilution of the viral p21 by normal p21 after cell fusion seems unlikely as microinjection of normal p21 protein into N-ras-transformed cells failed to revert the transformed phenotype (33) .
Most studies of tumor suppression have been carried out with fibroblasts, and it has been difficult to explain why fibroblasts transformed by a dominant oncogene revert to a normal phenotype after fusion with nontransformed cells (13) (14) (15) . In our system, this dilemma does not exist, because v-Ha-ras does not act as a dominant transforming gene but rather requires an additional transforming event to establish the tumor phenotype (18) . It is this final event, associated with the establishment of the autocrine IL-3 loop, that represents the recessive step being suppressed by cell fusion. This recessive step could correspond to the loss of a function down-regulating IL-3 expression. Fusion of tumor to PB-3c cells would then restore the status quo ante by providing the lost function. Hybrid-derived tumors (Table 1) , on the other hand, could develop by the same mechanism as the initial tumor; in fact, they share a similar latency time and some produced IL-3 like the parental tumorigenic line (Table 2) .
Having identified a tumor system where production of IL-3 is up-regulated during tumor formation and down-regulated in suppressed hybrids, it should now be possible to identify the DNA or RNA sequences in the IL-3 gene that respond to these two forms of regulation. The system described should facilitate the analysis of how suppressor genes regulate ultimate transforming events.
